Low-dose oral etoposide is an active option for patients with heavily pre-treated thymic epithelial tumors.

Margaret Ottaviano,Marianna Tortora,Mario Giuliano,Daniela Terracciano,Vincenzo Di Lauro,Fernanda Picozzi,Sara Parola,Vittorio Riccio,Pietro De Placido,Erica Pietroluongo,Antonietta Liotti,Evelina La Civita,Gianluca Guggino,Marcellino Cicalese,Carlo Curcio,Michele Longo,Gerardo Botti,Bruno Daniele,Sabino De Placido,Giovannella Palmieri

Low-dose oral etoposide is an active option for patients with heavily pre-treated thymic epithelial tumors.

2020

9074Background: Platinum based regimens are used in the first line setting for advanced Thymic Epithelial Tumors (TETs). Angiogenesis plays an important role in TETs: VEGF is overexpressed in TETs,...

Keywords:

Oncology
Internal medicine
oral etoposide
low dose
Medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations